CJC-1295 + Ipamorelin
A GHRH analog paired with a selective ghrelin-receptor agonist — the most-studied dual-pathway growth-hormone research combination.
Research Overview
This blend combines two compounds that act on separate receptors within the same axis. CJC-1295 without DAC (also called Mod GRF 1-29) is a modified GHRH(1-29) analog studied for binding at the GHRH receptor on somatotroph cells.
Ipamorelin is a selective pentapeptide agonist at the growth-hormone secretagogue receptor (ghrelin receptor), noted in the literature for its selectivity — minimal reported effect on cortisol or prolactin compared with earlier secretagogues.
Specifications
| Compound | CJC-1295 + Ipamorelin |
| Classification | Endocrine research compound |
| Constituents | CJC-1295 (no DAC) 5 mg — 3,367.8 g/mol Ipamorelin 5 mg — 711.85 g/mol |
| Molecular weight | Blend — see constituents |
| Sequence / Form | CJC-1295 (no DAC) 5 mg · Ipamorelin 5 mg |
| Purity | ≥98% HPLC, identity verified by mass spectrometry |
| Documentation | Batch-specific Certificate of Analysis available |
| Appearance | White lyophilized powder |
| Storage | Store sealed at 2–8°C. Long-term storage per certificate guidance. |
| Use | Research Use Only. Not for human or veterinary use. |
Quality Documentation
Every released lot is supported by quality-control documentation. Certificate access is presented by compound and lot where available. Cold-chain shipping is available where required; inventory is held under refrigerated conditions at our fulfillment center with temperature-logging protocols in place.
Research Use Only
This product is offered strictly for laboratory research use. It is not a drug, food, cosmetic, supplement, or consumer product, and is not intended for human or veterinary use.
